# Bioventus Inc.: Form 8-K, filed Mar 31, 2023

- Company: [Bioventus Inc.](/companies/bvs.md) (CIK 1665988)
- Form: 8-K
- Filed: 2023-03-31
- Accepted by EDGAR: Mar 31, 2023, 07:50 ET
- Period: 2023-03-31
- Accession: 0001628280-23-010022
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/bvs-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/

## Items reported

- Item 2.02: Results of operations
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1665988/000162828023010022/bvs-20230331.htm

Filed Mar 31, 2023.
Source: SEC EDGAR, the filing index for accession 0001628280-23-010022. Last ingested by Listed: Nov 2, 2026, 17:44 ET. No prices; not investment advice.